November 08, 2017
The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 06 November 2017, it purchased 20,000 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at 3.17p per Ordinary Share (the “Purchase”). Following the Purchase, Vulpes has a total direct and indirect interest in 55,217,431 equivalent to 18.71% of Proteome Sciences' total issued share capital.
The Company would also like to announce that by virtue of Martin Diggle being a Director of both Vulpes and the Company, he now has an interest in 55,217,431 Ordinary Shares of the Company representing 18.71% of the issued share capital of the Company.